Ocugen (OCGN) Short-term Investments (2017 - 2023)

Ocugen (OCGN) posted Short-term Investments of $8.5 million for Q1 2023, down 36.71% on a QoQ basis from $13.4 million in Q4 2022.

Ocugen (OCGN) Short-term Investments (2017 - 2023) Analysis & Trends

Ocugen's Short-term Investments history runs 4 years deep, the most recent figure standing at $8.5 million for Q1 2023.

Quarterly Short-term Investments changed N/A year-over-year to $8.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $8.5 million (changed N/A YoY) and the FY2022 annual result came in at $13.4 million, changed N/A from the prior year.
Short-term Investments was $8.5 million for Q1 2023 at Ocugen, down from $13.4 million in the prior quarter.
Across five years, Short-term Investments topped out at $13.4 million in Q4 2022 and bottomed at $5.0 million in Q1 2021.
A 3-year average of $7.4 million and a median of $5.0 million in 2021 frame the typical range for Short-term Investments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ocugen	63.79 Mn	63.79 Mn	-

Download Data